Table 2. Survival estimates.
| Comparison | Number of patients | Number of deaths | Median survival in months (95% CI) | Survival rates at 1, 2, and 5 years | Hazard ratio (95% CI) |
|---|---|---|---|---|---|
| ESPAC-1 | 144 | 120 | 18.6 (15.7, 23.6) | 67%, 42%, 18% | 1.0 |
| ESPAC-1 plus | 192 | 152 | 17.4 (15.8, 21.7) | 66%, 38%, 19% | 1.03 (0.81, 1.32)a |
| ESPAC-3 | 122 | 92 | 24.3 (19.8, 30.9) | 80%, 51%, 20% | 0.86 (0.66, 1.11)a |
| Overall | 458 | 364 | 19.6 (17.3, 22.0) | 70%, 43%, 19% | — |
| ESPAC-1 | |||||
| Obs | 69 | 63 | 16.9 (12.3, 24.8) | 64%, 39%, 10% | 1.0 |
| 5FU/FA | 75 | 57 | 21.7 (14.8, 27.3) | 70%, 44%, 27% | 0.70 (0.49, 1.01) |
| ESPAC-1 plus | |||||
| Obs. | 95 | 80 | 12.8 (10.2, 16.9) | 52%, 28%, 14% | 1.0 |
| 5FU/FA | 97 | 72 | 24.0 (18.8, 29.4) | 81%, 49%, 24% | 0.58 (0.42, 0.80) |
| ESPAC-3 | |||||
| Obs. | 61 | 47 | 20.3 (18.1, 31.7) | 79%, 48%, 20% | 1.0 |
| 5FU/FA | 61 | 45 | 25.9 (18.3, 36.3) | 82%, 54%, 20% | 0.89 (0.59, 1.33) |
| Overall | |||||
| Obs. | 225 | 190 | 16.8 (14.3, 19.2) | 63%, 37%, 14% | — |
| 5FU/FA | 233 | 174 | 23.2 (20.1, 26.5) | 77%, 49%, 24% | 0.70 (0.55, 0.88)b |
a
PLR=0.33.
b
Adjusted by trial. Bold value signifies P=0.003.